Patients receiving clopidogrel 75 mg/day as prescribed by their physician, and are extensive metabolizers by CYP2C19 genotype

Patients receiving prasugrel 5 or 10 mg/day as prescribed by their physician

Cardiovascular Disease

Medco Health Solutions, Inc

Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study

To assess the non-inferiority of clopidogrel therapy in patients with cardiovascular disease who are CYP2C19 extensive metabolizers (identified by genetic testing) compared to prasugrel therapy (non-genotyped) on the composite primary end point of cardiovascular death, hospitalization for acute coronary syndrome (nonfatal MI or unstable angina), nonfatal stroke or coronary revascularization

Number of hospitalizations and ER visits for other cardiovascular events not included in the primary composite endpoint.
the primary (composite) endpoint and the individual components of the primary end point in subjects who are CYP2C19 intermediate metabolizers (IM) with clopidogrel EM and prasugrel populations
the primary (composite) endpoint and the individual components of the primary end point in the population of CYP2C19 intermediate and extensive metabolizers with the prasugrel population.

Eric Stanek

Vice President, Research

Medco Health Solutions, Inc.

Bipolar Disorder

Schizophrenia

University of Iowa Hospitals and Clinics

Antipsychotics and Blood Vessel Function

Cardiovascular Complications of First-line, Second-generation Antipsychotics

% dilation of the brachial artery in response to 5 minutes of ischemia

% dilation of forearm blood vessels in response to pharmacological challenge measured using plethysmography

Requests for de-identified data may be presented to the principal investigator with a statistical analysis plan.

Jess G. Fiedorowicz

Assistant Professor

Saline starting before induction till entry to abdominal cavity

Remifentanil starting before induction till entry to abdominal cavity

Pre-Eclampsia

Hypertension, Pregnancy-Induced

Pregnancy Complications

1 microg/kg iv bolus before induction followed by 0.5 microg/kg/min infusion

Remifentanil

same volume iv bolus before induction followed by same volume infusion

esterase/insults

Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study

Antipsychotics and Blood Vessel Function

Remifentanil for General Anesthesia in Preeclamptics

Study of a New Anticoagulant Drug in Patients With Atrial Fibrillation

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne